WO2026013650 - RADIOLABELED STYRYLPYRIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF
National phase entry is expected:
Publication Number
WO/2026/013650
Publication Date
15.01.2026
International Application No.
PCT/IB2025/057108
International Filing Date
14.07.2025
Title **
[English]
RADIOLABELED STYRYLPYRIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF
[French]
STYRYLPYRIDINES RADIOMARQUÉES ET COMPOSITIONS PHARMACEUTIQUES ASSOCIÉES
Applicants **
JUBILANT DRAXIMAGE, INC.
Inventors
KULANGARA, Vijayaraj Kuniyil
PRASAD, M Umamaheshwar
NANDI, Indranil
SARWAL, Dinesh Kumar
PANNU, Kamaljeet
Priority Data
63/670,611
12.07.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CIPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2267 | |
| EPO | Filing, Examination, Granting | 14203 | |
| Japan | Filing, Examination, Granting | 2325 | |
| South Korea | Filing, Examination, Granting | 2441 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
25,976
Contact Us
Abstract[English]
The invention discloses radiopharmaceutical composition of Fluorine-18 (F18) labelled styrylpyridine compounds, for use as a medicament for the treatment or diagnosis of a disease or condition associated with build-up of amyloid-β (Aβ) aggregates. The invention further relates to polymorphic forms of precursors of F18 Florbetapir and their use for preparing F18 Florbetapir.[French]
L'invention concerne une composition radiopharmaceutique de composés de styrylpyridine marqués au fluor-18 (F18), destinée à être utilisée en tant que médicament pour le traitement ou le diagnostic d'une maladie ou d'un état associé à l'accumulation d'agrégats de bêta-amyloïde (Abêta). L'invention concerne en outre des formes polymorphes de précurseurs de F18 Florbetapir et leur utilisation pour préparer F18 Florbetapir.